Scientists take first steps towards urine test for cancer – Messenger Newspapers

Scientists have discovered a metabolite never found in mammals before which could pave the way for a urine test to detect a type of liver cancer for the first time.
Currently there is no definitive urine test used to diagnose any form of cancer, with most patients being diagnosed through surgery, ultrasound scans or blood tests which usually requires a trip to a hospital or doctor’s surgery.
But a new urine test could be developed to detect the beta-catenin mutated form of liver cancer after researchers at the Cancer Research UK Beatson Institute in Glasgow found a metabolite in mice.
Saverio Tardito, lead researcher on the project, said the number of people with liver cancer is expected to rise and new tools to detect and treat it earlier are needed.
“We were excited to discover this new metabolite which had never been described before in mammals, which is a good candidate for diagnostic testing as it’s specific to a particular type of liver cancer, can be easily detected in urine, and could potentially be used as a marker to monitor the growth of tumours,” he said.
The potential for the test was discovered by a team exploring a protein known to be prevalent in liver cancer – glutamine synthetase.
While studying this enzyme in normal liver tissue in mice, the team discovered a new metabolite not previously identified in mammals which is produced by the enzyme.
It appeared in high levels in mice with a specific type of liver tumour and the levels rose as the tumour grew.
The Glasgow team who discovered the metabolite, called N5-methylglutamine, also showed it appeared in urine when this tumour-promoting mutation of the gene beta-catenin is present, meaning it could be used to identify patients with this specific type of cancer.
Dr Tardito said: “We now plan further studies to investigate how early in liver cancer the metabolite appears, to identify how early a urine test could reliably diagnose the disease.”
Every year in the UK there are around 6,200 new liver cancer cases, with around 610 of those in Scotland.
North of the border, liver cancer rates are higher than the UK average and around a quarter of liver cancer patients have the beta-catenin mutated form of the disease.
Diagnosis of liver cancer is often late, with many patients diagnosed only when already receiving treatment for existing diseases such as cirrhosis or fatty liver disease.
But early, non-invasive testing could help catch the disease earlier, increase the effectiveness of existing treatments and boost development of new therapies.
We want our comments to be a lively and valuable part of our community – a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
This website and associated newspapers adhere to the Independent Press Standards Organisation’s Editors’ Code of Practice. If you have a complaint about the editorial content which relates to inaccuracy or intrusion, then please contact the editor here. If you are dissatisfied with the response provided you can contact IPSO here
© 2001-2022. This site is part of Newsquest’s audited local newspaper network. A Gannett Company. Newsquest Media Group Ltd, Loudwater Mill, Station Road, High Wycombe, Buckinghamshire. HP10 9TY. Registered in England & Wales | 01676637 |
Data returned from the Piano ‘meterActive/meterExpired’ callback event.
As a subscriber, you are shown 80% less display advertising when reading our articles.
Those ads you do see are predominantly from local businesses promoting local services.
These adverts enable local businesses to get in front of their target audience – the local community.
It is important that we continue to promote these adverts as our local businesses need as much support as possible during these challenging times.


Leave a Comment